Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett SM, Levin R, Meltzer MI, Schaffner W, Cieslak PR (2010) Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices...
Novel rabies vaccines that are less expensive and more immunogenic than current vaccines are needed to reduce the human death toll of rabies. Such vaccines would also allow for more widespread use of rabies vaccines in childhood immunization programs. A
Liaoning Chengda Biological Co., Ltd. is a high-tech enterprise established in June 2002 based on the international advanced viral vaccine production technology platform. It is the world's largest human rabies vaccine manufacturer. The company focuses on the research and development, production and s...
The WHO has accepted that generalized canine rabies vaccination is the only feasible method of limiting human rabies exposure and is also the most cost effective means of doing so [3]. Sole reliance on costly PEP, consisting of multiple vaccine and rabies immunoglobulin doses, and pre-exposure ...
Fig. 4. Predicted results from OLS regressions of the number of dogs vaccinated by hour, for (A) all vaccination strategies combined, (B) mobile static point (MSP), (C), MSP + capture vaccinate release (CVR), and (D) door-to-door vaccination (DDV) and oral rabies vaccine (ORV)...
Nagarajan, T.; Rupprecht, C.; Dessain, S.K.; Rangarajan, P.N.; Thiagarajan, D.; Srinivasan, V.A. Human monoclonal antibody and vaccine approaches to prevent human rabies.Curr. Top. Microbiol. Immunol.2008,317, 67–101. [Google Scholar] [PubMed] ...